ProKidney Corp [NASDAQ: PROK] jumped around 0.3 points on Wednesday, while shares priced at $3.26 at the close of the session, up 10.14%.
ProKidney Corp stock is now 92.33% up from its year-to-date (YTD) trading value. PROK Stock saw the intraday high of $3.41 and lowest of $2.77 per share. The company’s 52-week high price is 7.13, which means current price is +608.23% above from all time high which was touched on 07/09/25.
Compared to the average trading volume of 13.32M shares, PROK reached a trading volume of 7783987 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ProKidney Corp [PROK]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PROK shares is $5.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PROK stock is a recommendation set at 2.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for ProKidney Corp shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 30, 2025. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on September 30, 2024, representing the official price target for ProKidney Corp stock. Previously, the target price had yet another raise to $6, while Guggenheim analysts kept a Buy rating on PROK stock.
How has PROK stock performed recently?
ProKidney Corp [PROK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.38. With this latest performance, PROK shares gained by 47.51% in over the last four-week period, additionally plugging by 538.09% over the last 6 months – not to mention a rise of 92.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PROK stock in for the last two-week period is set at 67.10, with the RSI for the last a single of trading hit 0.25, and the three-weeks RSI is set at 0.26 for ProKidney Corp [PROK]. The present Moving Average for the last 50 days of trading for this stock 2.56, while it was recorded at 2.93 for the last single week of trading, and 1.66 for the last 200 days.
ProKidney Corp [PROK]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ProKidney Corp [PROK] shares currently have an operating margin of -33456.74% and a Gross Margin at -927.51%. ProKidney Corp’s Net Margin is presently recorded at -13752.18%.
ProKidney Corp (PROK) Capital Structure & Debt Analysis
ProKidney Corp (PROK) Efficiency & Liquidity Metrics
ProKidney Corp (PROK) Efficiency & Liquidity Metrics
From an operational efficiency perspective, ProKidney Corp. (PROK) effectively leverages its workforce, generating an average of -$355245.1 per employee. The company’s liquidity position is robust, with a Current Ratio of 11.48% and a Quick Ratio of 11.48%, indicating strong ability to cover short-term liabilities.
Earnings analysis for ProKidney Corp [PROK]
With the latest financial reports released by the company, ProKidney Corp posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.08. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PROK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ProKidney Corp go to 10.44%.
Insider trade positions for ProKidney Corp [PROK]
There are presently around $30.44%, or 41.47%% of PROK stock, in the hands of institutional investors. The top three institutional holders of PROK stocks are: MORGAN STANLEY with ownership of 14.45 million shares, which is approximately 19.034%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 9.34 million shares of the stock with an approximate value of $$22.98 million in PROK stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$9.78 million in PROK stock with ownership which is approximately 5.237%.
